Tissue Regenix appoints Daniel Lee as CEO

Writer,

Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

Regenerative medical devices company Tissue Regenix said it had appointed Daniel Lee as chief executive.

Lee was currently the head of the company's US operations, a role he'd commenced in January 2019.

Previous to that, he was CEO of Scaffold Biologics and Aperion Biologics.

At 8:50am: (LON:TRX) Tissue Regenix Group PLC share price was 0p at 0.41p